Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.42B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.99M
Average 1.35M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$46.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Revolution Medicines, Inc. NASDAQ:RVMD | $37.26B | $172.29 | Not rated | -23.3 | +128.15% |
Incyte Corporation NASDAQ:INCY | $24.66B | $120.97 | Undervalued | 13.7 | +13.87% |
Exelixis, Inc. NASDAQ:EXEL | $17.34B | $69.00 | Undervalued | 16.3 | +57.56% |
Relay Therapeutics, Inc. NASDAQ:RLAY | $4.00B | $18.09 | Not rated | -10.5 | +149.37% |
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -45.65% |
Tyra Biosciences, Inc. NASDAQ:TYRA | $1.38B | $20.03 | Not rated | -13.4 | -6.05% |
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | $850.77M | $9.45 | Not rated | -6.8 | -46.45% |
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | $814.71M | $7.86 | Not rated | -6.7 | -32.93% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $672.92M | $13.01 | Not rated | -9.8 | -43.87% |
Cullinan Therapeutics, Inc. NASDAQ:CGEM | $667.39M | $10.28 | Not rated | -4.0 | +4.01% |
Continue the stock analysis
Jump to another research area for this company.